Physician profile
Maryam Emami
NPI 1164876439
$2,437.00
in general payments reported to CMS, 2019-2025
36 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.97 · 2020: $127 · 2021: $481 · 2022: $519 · 2023: $547 · 2024: $330 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $247.23 | 2021-2023 | Eliquis |
| Glaxosmithkline, LLC. | $164.01 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $162.98 | 2020-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $151.73 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $138.94 | 2020-2024 | Mounjaro, Zepbound |
| Allergan, INC. | $115.46 | 2020-2021 | |
| Galderma Laboratories, L.P. | $71.35 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.27 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $67.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.75 | 2021 | |
| Exact Sciences Corporation | $61.29 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $59.18 | 2023-2024 | |
| Stryker Corporation | $58.76 | 2021 | |
| Radius Health, INC. | $57.48 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56.87 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $53.02 | 2019-2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $50.95 | 2022 | |
| Novo Nordisk INC | $46.50 | 2023-2025 | Ozempic, Wegovy |
| Dexcom, INC. | $45.72 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $43.29 | 2023 | Myrbetriq, Veozah |
| Merz Pharmaceuticals, LLC | $43.15 | 2023 | Xeomin |
| Paratek Pharmaceuticals, INC. | $42.52 | 2024 | Nuzyra |
| Abbott Laboratories | $31.68 | 2023 | Freestyle Libre 2 |
| Phadia US INC. | $30.87 | 2019-2022 | |
| Amarin Pharma, INC. | $28.15 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $27.80 | 2023-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Nestle Healthcare Nutrition INC. | $22.35 | 2022 | |
| Neurelis, INC. | $22.00 | 2022 | |
| Bioventus LLC | $21.00 | 2025 | Supartz Fx Sodium Hyaluronate |
| Biohaven Pharmaceuticals, INC. | $19.72 | 2021 | |
| Merz North America, INC. | $18.72 | 2024 | |
| Endo Pharmaceuticals INC. | $17.00 | 2020 | |
| Biogen, INC. | $12.09 | 2021 | |
| Boston Scientific Corporation | $11.53 | 2020 | |
| Esperion Therapeutics, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Emami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.